Dyadic International rapidly developed stable C1 cell lines and produced purified Bundibugyo Ebola virus antigens within approximately 15 days, delivering them for preclinical evaluation of a potential non-mRNA vaccine. This rapid production is crucial amid the active Bundibugyo ebolavirus outbreak, which currently lacks approved vaccines or treatments. Dyadic's C1 platform offers a scalable, cost-effective alternative to traditional methods, potentially accelerating vaccine and antibody development during health emergencies. The company aims to expand its platform's adoption and commercial opportunities in biologics manufacturing, supported by collaborations with global health organizations and funding from the Gates Foundation.
Curve DAO has approved yRisk as the new risk-management provider for its crvUSD and Llamalend platforms, replacing LlamaRisk. yRisk, led by two primary Resupply developers, will oversee risk assessment for a year, receiving funding through revocable ...
The IMF announced that El Salvador's Bitcoin accumulation since June 27, 2025, originated from private donations rather than public resources, addressing concerns about government Bitcoin purchases. This clarification came as part of a staff-level ag...
Rayonier Inc. has been rated a Buy following its merger with PotlatchDeltic, which nearly doubled its share count and expanded its timberland and manufacturing assets. The company now offers a 5% dividend yield and improved cash flow, though it faces...
Global government bond yields surged this week as investors grapple with rising government borrowing, energy price pressures, and persistent inflation uncertainty. The shift away from globalization toward protectionism and geopolitical tensions is se...
Bitcoin surged over 25% in August, marking its strongest monthly gain since November 2024, driven by increased market volatility and resilience despite regulatory and security challenges. Fidelity warns this rally may be a temporary bounce within an ...
